论文部分内容阅读
目的:观察雾化吸入普米克令舒治疗慢性阻塞性肺病急性加重期(AECOPD)的临床疗效和安全性。方法:40例患者随机分成两组,雾化组采用雾化吸入布地奈德混悬液2 mg/次,2次/d;口服组采用口服强的松30 mg/d。结果:治疗后两组的呼吸困难,肺功能以及动脉血气分析均有所改善,雾化组不良反应少。结论:中重度AECOPD患者可应用雾化吸入普米克令舒的治疗方法,从而减少不良反应的发生。
Objective: To observe the clinical efficacy and safety of atomization inhalation of pulmicort in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Forty patients were randomly divided into two groups. The inhaled budesonide suspension was nebulized 2mg / time, 2 times / d in the nebulized group. The oral group was given oral prednisone 30mg / d. Results: After treatment, dyspnea, pulmonary function and arterial blood gas analysis were improved in both groups, with little adverse reaction in the atomization group. Conclusion: Moderate and severe AECOPD patients can apply inhalation of pulmonic therapy, thereby reducing the incidence of adverse reactions.